The ruthenium‐based anticancer agent BOLD‐100/KP1339 has shown promising results in
several in vitro and in vivo tumour models as well as in early clinical trials. However, its …

The organometallic AuI bis‐N‐heterocyclic carbene complex [Au (9‐methylcaffeine‐8‐
ylidene) 2]+(AuTMX2) was previously shown to selectively and potently stabilise telomeric …

The combination of more than one bioactive moiety in a multitargeted anticancer agent may
result in synergistic activity of its components. Using this concept, bioorganometallic …

Abstract Cyclometalated (C^ N^ C) AuIII complexes bearing functionalized N‐heterocyclic
carbene (NHC) ligands provide a high‐yielding, modular route to bioconjugated and …

Abstract Anticancer‐active RuII–η6‐p‐cymene complexes of bioactive 2‐
pyridinecarbothioamide ligands have been shown to have high selectivity for plectin and …

A series of six highly lipophilic Cp‐substituted molybdenocenes bearing different bioactive
chelating ligands was synthesized and characterized by NMR spectroscopy, mass …

Two‐step functionalization of 4‐diphenylphosphino benzoic acid with biotin afforded 2‐
(biotinyloxy) ethyl 4‐(diphenylphosphanyl) benzoate (LP), that was subsequently used to …

Understanding binding site preferences in biological systems as well as affinities to binding
partners is a crucial aspect in metallodrug development. We here present a mass …

Dinuclear metallodrugs offer much potential in the development of novel anticancer
chemotherapeutics as a result of the distinct interactions possible with bio‐macromolecular …

In this study, we report the first successful immobilisation of a known cytoactive [Ru (η6‐
arene)(C2O4) PTA](RAPTA) complex to a biologically inert polyacrylamide nanoparticle …